The 2011 ESPEN Arvid Wretlind lecture: Cancer cachexia: The potential impact of translational research on patient-focused outcomes

Clinical Nutrition

Volumn 31, Issue 5, 2012, Pages 577-582

  Fearon, K C H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cachexia; Cancer; Mechanisms; Outcomes; Therapy

Indexed keywords

IBUPROFEN; ICOSAPENTAENOIC ACID; MEGESTROL ACETATE; TRIACYLGLYCEROL LIPASE;

ADL DISABILITY; ADVANCED CANCER; ANOREXIA; CACHEXIA; CALORIC INTAKE; DIET SUPPLEMENTATION; ENERGY BALANCE; EXERCISE; HUMAN; HYPOGONADISM; INFLAMMATION; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; NUTRITIONAL COUNSELING; PANCREAS CANCER; PHYSICAL ACTIVITY; PROTEIN DIET; PROTEIN HOMEOSTASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; TRANSLATIONAL RESEARCH; WEIGHT REDUCTION;

CACHEXIA; EXERCISE; HUMANS; INFLAMMATION; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT (HEALTH CARE); TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84866611475     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2012.06.012     Document Type: Review

References (36)

1. Calman K.C. Malignancy: cancer cachexia. Br J Hosp Med 1982, 27:28-34.
2. Fearon K.C., Voss A.C., Hustead D.S. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006, 83:1345-1350. Cancer Cachexia Study Group.
3. Kaasa S., Loge J.H., Fayers P., Caraceni A., Strasser F., Hjermstad M.J., et al. Symptom assessment in palliative care: a need for international collaboration. J Clin Oncol 2008, 26:3867-3873.
4. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12:489-495.
5. Evans W.J., Morey J.E., Argiles J., Bales C., Baracos V., Guttridge D., et al. Cachexia: a new definition. Clin Nutr 2008, 27:793-799.
6. Baracos V.E., Reiman T., Mourtzakis M., Gioulbasanis I., Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010, 91:1133S-1137S.
7. Tan B.H., Birdsell L.A., Martin L., Baracos V.E., Fearon K.C. Sarcopenia in an overweight obese patient is an adverse prognostic factor in pancreatic cancer. Clin Can Res 2009, 15:6973-6979.
8. Fearon K.C. Cancer cachexia and fat-muscle physiology. N Engl J Med 2011, 365:565-567.
9. Das S.K., Eder S., Schauer S., Diwoky C., Temmel H., Guertl B., et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333:233-238.
10. Falconer J.S., Fearon K.C.H., Plester C.E., Ross J.A., Carter D.C. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994, 219:325-331.
11. Wigmore S.J., Plester E., Ross J.A., Fearon K.C. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997, 84:196-197.
12. Falconer J.S., Fearon K.C., Ross J.A., Elton R., Wigmore S.J., Garden O.J., et al. Acute phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995, 75:2077-2082.
13. Bennani-Baiti N., Walsh D. Animal models of the cancer anorexia-cachexia syndrome. Support Care Cancer 2011, 19:1451-1463.
14. Knox L.S., Crosby L.O., Feurer I.D., Buzby G.P., Miller C.L., Mullen J.L. Energy expenditure in malnourished cancer patients. Ann Surg 1983, 197:152-162.
15. Tan B.H.L., Fearon K.C.H. Cytokine gene polymorphism and susceptibility to cachexia. Curr Opin Support Palliat Care 2010, 4:243-248.
16. Deans D.A., Tan B.H., Ross J.A., Rose-Zerilli M., Wigmore S.J., Howell W.M., et al. Cancer cachexia is associated with the IL10-1082 gene promoter polymorphism in patients with gastroesophageal malignancy. Am J Clin Nutr 2009, 89:1164-1172.
17. Sun Y., Yu Z., Zhang D., Zhang J., Song B., Zheng H. Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population. Mol Diagn Ther 2010, 14:95-100.
18. Tan B.H.L., Fladvad T., Braun T.P., Vigano A., Strasser F., Deans D.A.C., et al. P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol Med 2012, [Epub ahead of print].
19. Gray C., MacGillivray T.J., Eeley C., Stephens N.A., Beggs I., Fearon K.C., et al. Magnetic resonance imaging with K-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin Nutr 2011, 30:106-111.
20. Stephens N.A., Skipworth R.J.E., MacDonald A.J., Greig C.A., Ross J.A., Fearon K.C.H. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle 2011, 2:111-117.
21. Bostrom P., Andersson L., Li L., Perkins R., Hojlund K., Boren J., et al. The assembly of lipid droplets and its realtion to cellular insulin sensitvity. Biochem Soc Trans 2009, 37:981-985.
22. Crane J.D., Devries M.C., Safdar A., Hamadeh M.J., Tarnopolsky M.A. The effect of aging on human skeletal muscle mitochondrial and intramyocellular lipid ultrastructure. J Gerontol A Biol Sci Med Sci 2010, 65:119-128.
23. Amati F., Dube J.J., Alvarez-Carnero E., Edreira M.M., Chomentowski P., Coen P.M., et al. Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained atheletes?. Diabetes 2011, 60:2588-2597.
24. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004, 18:39-51.
25. Gallagher I.J., Stephens N.A., Macdonald A.J., Skipworth R.J., Husi H., Greig C.A., et al. Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies. Clin Cancer Res 2012, 18:2817-2827.
26. Palomares M.R., Sayre J.W., Shekar K.C., Lillington L.M., Chelbowski R.T. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996, 78:2119-2126.
27. Skipworth R.J., Moses A.G., Sangster K., Sturgeon C.M., Voss A.C., Fallon M.T., et al. Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer 2011, 19:391-401.
28. Stephens N.A., Gray C., Macdonald A.J., Tan B.H., Gallagher I.J., Skipworth R.J., et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin Nutr 2012, [Epub ahead of print].
29. Skipworth R.J., Stene B.G., Dahele M., Hendry P.O., Small A.C., Blum D., et al. Patient-focused endpoints in advanced cancer: criterion-based validation of accelerometer-based activity monitoring. Clin Nutr 2011, 30:812-821. European Palliative Care Research Collaborative (EPCRC).
30. Ferriolli E., Skipworth R.J., Hendry P.O., Scott A., Stensteth J., Dahele M., et al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy?. J Pain Symptom Manage 2012, [Epub ahead of print].
31. Ochmann U., Jorres R.A., Nowak D. Long-term efficacy of pulmonary rehabilitation: a state of the art review. J Cardiopulm Rehabil Prev 2012, 32:117-126.
32. Fearon K.C. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008, 44:1124-1132.
33. Moses A.W., Slater C., Preston T., Barber M.D., Fearon K.C. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004, 90:996-1002.
34. McMillan D.C., Wigmore S.J., Fearon K.C., O'Gorman P., Wright C.E., McArdle C.S. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weigh loss. Br J Cancer 1999, 79:495-500.
35. Greig C.A., Gray C., Johns N., MacDonald A., Stephens N.A., Wall L., et al. Phase I/II trial of formoterol fumarate combined with megestrol acetate in patients with advance malignancy. J Cachexia Sarcopenia Muscle 2011, 2:259-260.
36. Zhou X., Wang J.L., Lu J., Song Y., Kwak K.S., Jiao Q., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.